Serum Neurofilament Light Chain as a Biomarker for CIDP Diagnosis, Severity, and Treatment Outcome.

Neurol Neuroimmunol Neuroinflamm · 2025 · PMC12153944 · PMID 40472292

Europe PMC DOI

hedged sentence

0.0680

closest p · 1.4× alpha

0.0680

boldest claim

The sentences

showed a trendp = 0.068so close (0.05 < p ≤ 0.1)

Although not reaching statistical significance, the INCAT-ODSS showed a trend toward higher disability in patients with typical CIDP (typical: 4 (5); atypical: 2.5 (2); p = 0.068).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.